ScoreHaematology
BALL score for relapsed/refractory CLL
Classifies previously treated chronic lymphocytic leukaemia patients into three survival risk groups.
Updated 30 October 2026
When to use it
Relapsed or refractory CLL before starting a new line, with targeted therapy (BTKi, idelalisib, venetoclax) or chemoimmunotherapy.
What it needs
- Serum β2-microglobulin ≥ 5 mg/L
- Anaemia: haemoglobin < 110 g/L (women) or < 120 g/L (men)
- LDH above the upper limit of normal
- Less than 24 months since starting the last therapy
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 1 | Low risk (2-year survival ≈ 90 %) |
| 2–3 | Intermediate risk (2-year survival ≈ 80 %) |
| ≥ 4 | High risk (2-year survival ≈ 56 %) |
Practical tip
It uses only routine data (β2-microglobulin, haemoglobin, LDH and start date of last therapy), without genetic testing.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
